VOR Utang marang Ekuitas vorbio.com

Logo korporat perusahaan Vor Bio Inc. (VOR)

Vor Biopharma Inc. (VOR) management aims to implement advanced methods for protecting healthy tissues during chemotherapy, shifting safety standards in oncology. The operating model relies on outsourcing gene modification and batch production to proven laboratories, which accelerates trials. The stock's characteristics regarding the total debt-to-equity ratio, which stands at 0.00, confirm the resilience of the company as it develops unique cell therapy in a niche with high technological barriers.

VOR: Rasio Total Utang marang Ekuitas vorbio.com 04.07.2022 - 29.10.2026

Vor Bio Inc. - rincian analitis lan metrik utama (VOR)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Vor Biopharma|VOR - Prakiraan konsensus analis
- data kapitalisasi pasar:
Nilai pasar Vor Biopharma|VOR - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Vor Biopharma|VOR - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku vorbio.com|VOR - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Vor Biopharma Inc.|VOR - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Vor Biopharma Inc.|VOR - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Vor Biopharma|VOR - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Vor Biopharma|Likuiditas cepet vorbio.com
- informasi bathi lan kelipatan valuasi:
VOR - Penghasilan resik perusahaan
Pambiji fundamental perusahaan:Vor Biopharma, VOR
Barang utama vorbio.com

Developing cell therapies to protect bone marrow requires significant R&D capital expenditures. This ratio compares the total liabilities of Vor Biopharma Inc. (VOR) to its net assets, measuring the degree of financial autonomy. By analyzing the current total debt leverage, an investor assesses the risk of over-indebtedness in the absence of stable revenue. An upward trend in the curve signals the danger of capital depreciation. This chart reflects market confidence in the sustainability of the business model.

Pesaing wigati

TGTX (TG Therapeutics) - Total Utang marang Modal|Total Utang marang Modal Arcellx Inc|Utang marang Ekuitas Disc Medicine Corp (IRON)|Syndax Corp - Rasio Utang marang Ekuitas|Total Utang marang Modal KURA (Kura Oncology, Inc.)|ADCT - Rasio Total Utang marang Ekuitas|Foghorn - Total Utang marang Modal|Utang marang Modal Nkarta, Inc.|coeptistx.com (COEP) - Utang marang Ekuitas|Actinium Corp - Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas ESLA|CASI: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal MRKR|Utang marang Ekuitas INAB (IN8bio Inc.)|Utang marang Ekuitas Eterna Therapeutics Inc. ERNA|GT Biopharma Corporation - Utang marang Ekuitas|APTO - Utang marang Ekuitas|Utang marang Modal biopathholdings.com|MEI Pharma (MEIP) - Utang marang Ekuitas|Utang marang Modal Vincerx Pharma (VINC)